|
|
|
|
Automated Proof Of Monoclonality
|
Discover the Cell Metric® X by Advanced Instruments – a game-changer in cell line development. Our AI-driven technology swiftly identifies single cells in microplates, eliminating manual labor and subjective errors. It efficiently differentiates cells from debris, speeding up the critical monoclonality proof process. Streamline your therapy development with precision and ease. Download our paper to learn how Cell Metric X is revolutionizing the future of specialized medicine.
|
|
|
|
|
By Kristin Yarema, Ph.D., President and CEO, Poseida Therapeutics
|
Poseida Therapeutics' President and CEO, Kristin Yarema, Ph.D., details why allogenic CAR-T compares favorably with autologous CAR-T, and why, in many ways, allo has advantages that auto cannot hope to match.
|
|
|
|
Explore the evolving regulatory landscape for cell and gene therapies in 2024 including the increasing speed availability of these therapies by enabling manufacturing processes and standards development.
|
|
|
|
|
Trends In Next-Generation Delivery Technologies
|
Article | Precision NanoSystems
|
Learn how lipid nanoparticles are enabling a new generation of engineered cell therapies with a push toward more complex cell engineering and gene editing for allogeneic therapies.
|
|
|
|
|
|
|
Adeno-Associated Virus: Enabling Genomic Medicine
|
White Paper | Bio-Rad Laboratories, Inc.
|
Since the first rAAV-based therapy was approved by the FDA, application of gene therapies utilizing rAAV vectors has exploded and active clinical programs are being fast-tracked for clinical approval.
|
|
|
|
|
The Need For Mass-Produced Spheroids
|
Article | Corning Life Sciences
|
Researchers looking for reliable ways to recapitulate physiological conditions are turning to spheroids and other 3D objects, seeking ways to mass-produce 3D models for various applications.
|
|
|
|
Are Bioreactors The New ‘Fish Tanks’?
|
Article | By Marcelo Szpilman, Eppendorf SE
|
By exploring innovative approaches to scaling up animal cell growth in cutting-edge bioreactor systems, foodtech companies are poised to offer healthier, safer, more sustainable fish for consumers.
|
|
|
|
|
|
|
|
As the patient’s immune cells are the starting materials, inherent biological variability leads to CAR-T manufacturing. Additional critical raw materials also have batch-to-batch variability, which means the entire production process is a constant balancing act of adjusting the manufacturing process to create standardized manufacturing. Join Cell & Gene Live for a discussion on practical ways to overcome the challenges associated with batch-to-batch variation. Registration is free thanks to the support of Entegris.
|
|
|
|
|
|
|
|
|
Connect With Cell & Gene: |
|
|
|